Table 2 Clinical characteristics of ALL patients (n = 11)
From: Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia
Patient No. | Age (years) | Gender | T or B-ALL | Cell count (×109/L) | LDH (U/L) | Extramedullary infiltration | Karyo-type | Molecular features | ||
|---|---|---|---|---|---|---|---|---|---|---|
WBC | HB (g/L) | PLT | ||||||||
1 | 31 | F | B | 12.29 | 75 | 32 | 349 | Yes | Complex | MYC,P16,E2A |
2 | 18 | M | B | 33.64 | 81 | 65 | 330 | Yes | 46,XY | IGH5′ |
3 | 29 | F | T | 286.68 | 58 | 71 | 362 | Yes | NA | – |
4 | 22 | M | T | 3.87 | 137 | 305 | 162 | Yes | NA | – |
5 | 21 | M | B | 2.85 | 63 | 9 | 542 | No | 46,XY | IGH |
6 | 71 | M | B | 141.25 | 102 | 85 | 590 | Yes | NA | NA |
7 | 58 | F | B | 124 | 82 | 19 | 4252 | Yes | t(4;11)(q25;q22) | MFF/AF4 |
8 | 36 | M | B | 51.62 | 96 | 59 | 283 | Yes | Complex | – |
9 | 23 | M | T | 247.36 | 66 | 37 | 4623 | Yes | NA | P16,E2A,IGH |
10 | 59 | M | B | 62.97 | 101 | 11 | 395 | Yes | t(9;22)(q34;q11) | BCR/ABL,P16 |
11 | 53 | M | B | 87.02 | 115 | 9 | 1521 | Yes | t(9;22)(q34;q11) | BCR/ABL |